secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2022-02-18T23:59:59+00:00
Accession:  0001654954-22-001828
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma appoints Manu Ohri as CFO, replacing Gavin Choy as Acting CFO
--------------------------------------------------------------------------

- Manu Ohri appointed CFO effective Feb 14, 2022; Gavin Choy ceases as Acting CFO.
- Annual base salary of $325,000; target bonus up to 40% of base salary.
- Stock award of 25,000 shares and option to purchase 175,000 shares vesting over 3 years.
- Options fully accelerate upon a change of control; employment agreement to be signed.
- Ohri is a CPA with prior CFO experience at ToughBuilt Industries and Big 4 background.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/0001654954-22-001828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000165495422001828/gtbp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-001828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer